Last reviewed · How we verify
NCT03579914
Effect of Intravenous Metoprolol Combining RIC on Myocardial Protection in STEMI Patients
NA trial testing intravenous Placebo in Anterior Myocardial Infarction in 1,206 participants. Completed in 30 August 2021.
31 August 2020
Quick facts
| Lead sponsor | Harbin Medical University |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | factorial |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 1,206 |
| Start date | 28 November 2017 |
| Primary completion | 31 August 2020 |
| Estimated completion | 30 August 2021 |
| Sites | 16 locations across China |
Drugs / interventions tested
- intravenous Placebo
- Metoprolol Injectable Product — full drug profile →
- Romote Ischemic Conditioning (RIC)
- Metoprolol & RIC
Conditions studied
- Anterior Myocardial Infarction — all drugs for Anterior Myocardial Infarction →
- Heart Failure — all drugs for Heart Failure →
Sponsor
Harbin Medical University
Who can join
Adults 18 to 80, any sex, with Anterior Myocardial Infarction or Heart Failure. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The main purpose of this study is to compare the myocardial protection effect of intravenous metoprolol combined with remote ischemic conditioning (RIC) and single treatment before reperfusion in Chinese patients with anterior STEMI. This study sought to find possible strategies to further improve myocardial protection in Chinese patients with anterior STEMI.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Beta-blockers for suspected or diagnosed acute myocardial infarction.
Safi S, Sethi NJ, Nielsen EE, Feinberg J, et al · · 2019 · cited 24× · PMID 31845756 · DOI 10.1002/14651858.cd012484.pub2
Verify or expand the search:
- PubMed search for NCT03579914
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Harbin Medical University trials
Trials by the same sponsor.
- NCT07471815 — Camrelizumab Plus Risedronate and Chemotherapy for Triple-Negative Breast Cancer: An Exploratory Clinical Study on Mecha · Phase 2 · active not recruiting
- NCT07187674 — The Neoadjuvant Treatment of Early High-risk Triple Negative Breast Cancer With HRD Positive With Iparomlimab and Tuvonr · NA · not yet recruiting
- NCT07161791 — Camrelizumab, Pirfenidone, and Chemotherapy in the Treatment of Advanced Triple-Negative Breast Cancer · Phase 1, PHASE2 · not yet recruiting
- NCT07033624 — Cardiovascular Risk Early Screening and Warning in Harbin : A Prospective Cohort Study · not yet recruiting
- NCT06947148 — The Impact of Comprehensive Post Hospital Management Based on DHI on Cardiac Function in Patients With HF · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03579914 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Harbin Medical University
- Last refreshed: 4 November 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03579914.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing